GlassScriptPhysician profile
Deepna Deepak Jaiswal
NPI 1447541594
$49,411.40
in general payments reported to CMS, 2019-2025
59 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $44K · 2021: $1,212 · 2022: $359 · 2023: $610 · 2024: $710 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.02 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42,333.57 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $3,643.71 | 2019-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $396.18 | 2019-2025 | |
| Genentech USA, INC. | $239.32 | 2019-2025 | Tecentriq |
| Puma Biotechnology, INC. | $186.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $178.15 | 2019-2024 | |
| Astellas Pharma US INC | $175.90 | 2019-2024 | Padcev |
| Genzyme Corporation | $152.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $132.35 | 2019-2025 | Keytruda, Lenvima |
| Lilly USA, LLC | $131.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.04 | 2019-2025 | |
| Celgene Corporation | $99.22 | 2022-2024 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $94.24 | 2019-2025 | Opdivo |
| Amgen INC. | $92.83 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Glaxosmithkline, LLC. | $85.87 | 2020-2025 | Zejula, Jemperli, Ojjaara |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepna Jaiswal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.